title: Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
abstract: Concomitant treatment of tuberculosis (TB) and HIV is recommended and improves outcomes. Bedaquiline is a novel drug for the treatment of multidrug-resistant (MDR) TB; combined use with antiretroviral drugs, nevirapine, or ritonavir-boosted lopinavir (LPV/r) is anticipated, but no clinical data from coinfected patients are available. Plasma concentrations of bedaquiline and its M2 metabolite after single doses were obtained from interaction studies with nevirapine or LPV/r in healthy volunteers. The antiretrovirals' effects on bedaquiline and M2 pharmacokinetics were assessed by nonlinear mixed-effects modeling. Potential dose adjustments were evaluated with simulations. No significant effects of nevirapine on bedaquiline pharmacokinetics were identified. LPV/r decreased bedaquiline and M2 clearances to 35% (relative standard error [RSE], 9.2%) and 58% (RSE, 8.4%), respectively, of those without comedication. As almost 3-fold (bedaquiline) and 2-fold (M2) increases in exposures during chronic treatment with LPV/r are expected, dose adjustments are suggested for evaluation. Efficacious, safe bedaquiline dosing for MDR-TB patients receiving antiretrovirals is important. Modeling results suggest that bedaquiline can be coadministered with nevirapine without dose adjustments. The predicted elevation of bedaquiline and M2 levels during LPV/r coadministration may be a safety concern, and careful monitoring is recommended. Further data are being collected in coinfected patients to determine whether dose adjustments are needed. (These studies have been registered at ClinicalTrials.gov under registration numbers NCT00828529 [study C110] and NCT00910806 [study C117].).
authors.affiliation: Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden elin.svensson@farmbio.uu.se.
authors.forename: Elin M
authors.initials: EM
authors.lastname: Svensson
authors.affiliation: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: Kelly E
authors.initials: KE
authors.lastname: Dooley
authors.affiliation: Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
authors.forename: Mats O
authors.initials: MO
authors.lastname: Karlsson
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D060085:Coinfection / Q000188:drug therapy; D064687:Diarylquinolines / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D004338:Drug Combinations; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D061466:Lopinavir / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D019829:Nevirapine / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D000995:Antitubercular Agents; D064687:Diarylquinolines; D004338:Drug Combinations; C558899:lopinavir-ritonavir drug combination; D061466:Lopinavir; C493870:bedaquiline; D019829:Nevirapine; D019438:Ritonavir
references.citation: Tuberculosis (Edinb). 2002;82(2-3):91-6
references.pmid: 12356460
references.citation: Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
references.pmid: 16023764
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6
references.pmid: 22391540
references.citation: Antimicrob Agents Chemother. 2014 Sep;58(9):5315-24
references.pmid: 24957842
references.citation: Drug Metab Dispos. 2002 Jul;30(7):795-804
references.pmid: 12065438
references.citation: Science. 2005 Jan 14;307(5707):223-7
references.pmid: 15591164
references.citation: J Pharmacol Exp Ther. 1996 Apr;277(1):423-31
references.pmid: 8613951
references.citation: N Engl J Med. 2010 Feb 25;362(8):697-706
references.pmid: 20181971
references.citation: J Antimicrob Chemother. 2014 Sep;69(9):2310-8
references.pmid: 24860154
references.citation: N Engl J Med. 2014 Aug 21;371(8):723-32
references.pmid: 25140958
references.citation: Br J Clin Pharmacol. 1997 Aug;44(2):190-4
references.pmid: 9278209
references.citation: AIDS Res Treat. 2012;2012:874083
references.pmid: 22829999
references.citation: Clin Pharmacokinet. 2003;42(3):223-82
references.pmid: 12603174
references.citation: Toxicol In Vitro. 2010 Aug;24(5):1417-25
references.pmid: 20430096
references.citation: J Bras Pneumol. 2008 Nov;34(11):942-9
references.pmid: 19099101
references.citation: N Engl J Med. 2011 Oct 20;365(16):1471-81
references.pmid: 22010913
references.citation: Nat Chem Biol. 2007 Jun;3(6):323-4
references.pmid: 17496888
references.citation: Lancet. 2006 Nov 4;368(9547):1575-80
references.pmid: 17084757
references.citation: Antimicrob Agents Chemother. 2013 Jun;57(6):2780-7
references.pmid: 23571542
references.citation: Expert Opin Drug Saf. 2006 Jul;5(4):567-83
references.pmid: 16774494
references.citation: Br J Clin Pharmacol. 1998 Aug;46(2):111-6
references.pmid: 9723818
references.citation: Comput Methods Programs Biomed. 1999 Jan;58(1):51-64
references.pmid: 10195646
references.citation: Antimicrob Agents Chemother. 2013 May;57(5):2199-203
references.pmid: 23459487
references.citation: Clin Pharmacol Ther. 2003 May;73(5):406-16
references.pmid: 12732841
references.citation: Am J Ther. 2016 Mar-Apr;23(2):e521-30
references.pmid: 24284652
references.citation: Comput Methods Programs Biomed. 2011 Jan;101(1):72-9
references.pmid: 20627442
references.citation: Jpn J Infect Dis. 2008 May;61(3):202-4
references.pmid: 18503169
references.citation: AAPS J. 2011 Jun;13(2):143-51
references.pmid: 21302010